Aortic Blood Pressure
Conditions
Keywords
sick sinus syndrome, heart rate, aortic blood pressure, artificial pacemaker, beta-blockers, ivabradine
Brief summary
This study is divided into two parts: * The first part evaluates the acute effect of non-pharmacological heart rate change on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker * The second part evaluates the acute effects of atenolol, nebivolol and ivabradine on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker at different pacing rate levels
Detailed description
Patients with sick sinus syndrome and a double-chamber cardiac pacemaker are studied. * To investigate the role of non-pharmacological heart rate change on central hemodynamics in the first part of the study, the investigators acutely change pacing rate from atrial paced-atrial sensed (AAI)-mode 60 to 40 to 90 bpm and obtain hemodynamic parameters noninvasively after a short stabilisation period after each pacemaker rate change. * Subsequently, to investigate the acute effects of beta-blockers or ivabradine on central hemodynamics in the second part of the study, the investigators obtain central hemodynamic parameters noninvasively after acute administration of atenolol, nebivolol or ivabradine at the same pacing rate levels used in the first part of the study (AAI-mode 60, 40 and 90 bpm).
Interventions
DEVICEAAI 40 bpm
Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
DEVICEAAI 60 bpm
Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
DEVICEAAI 90 bpm
Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
DRUGAtenolol Pill
50 or 100 mg of atenolol is administered to subjects in the second part of the study
DRUGNebivolol Pill
5 mg of nebivolol is administered to subjects in the second part of the study
DRUGIvabradine Pill
5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
Sponsors
Tartu University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age 18-75 years; * dual-chamber pacemaker implanted due to sick sinus syndrome at least six months before; sinus rhythm
Exclusion criteria
* average seated office brachial systolic BP ≥160 mmHg and/or diastolic BP ≥ 100 mmHg; atrial pacing \<40%; * ventricular pacing \>25%; * unpaced QRS \>120 ms and/or QTc \>500 ms on 12-lead ECG; * atrioventricular blockage at AAI-mode 90 bpm; resting HR \>60 bpm at AAI-mode 40 bpm; irregular heart rate; * automatic mode switching \>10%; * implantable cardioverter defibrillator or cardiac resynchronisation therapy pacemaker; treatment with digoxin, class Ic or III antiarrhythmic drugs; * history of acute coronary syndrome; * stable angina pectoris; * heart failure with reduced left ventricular ejection fraction; * history of cerebrovascular event; * diabetes mellitus; * chronic kidney disease with eGFR \<30 ml/min/m2; * peripheral artery disease; * clinically relevant heart valve disease; * active cancer; * acute or chronic inflammatory disease; * severe chronic respiratory or liver disease; * pregnancy or breastfeeding * contraindication or intolerance to atenolol, nebivolol, ivabradine or adjuvants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| First part of the study: central systolic blood pressure | 3 minutes after heart rate change | — |
| Second part of the study: systolic blood pressure amplification | 3 hours after drug administration and 3 minutes after heart rate change | difference between peripheral and central systolic blood pressure |
Outcome results
None listed